Core Viewpoint - Zhijiang Biotech (688317.SH) is expected to report a net loss attributable to shareholders of the parent company for the year 2025, with estimates ranging from -32 million to -47 million yuan, indicating a significant decline in profitability compared to the previous year [1] Financial Performance - The projected net loss represents an increase in losses of 80.46 million to 95.46 million yuan compared to the same period last year, reflecting a year-on-year reduction in loss margin of 63.13% to 74.89% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -39 million and -58 million yuan, with a reduction in losses of 70.27 million to 89.27 million yuan compared to the previous year, indicating a year-on-year reduction in loss margin of 54.78% to 69.60% [1] Reasons for Performance - The primary reasons for the company's expected losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate on self-produced reagent products to 13%, which has negatively impacted revenue [1] - Additional factors contributing to the losses include a decrease in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1] - The narrowing of losses this year is attributed to a reduction in asset impairment losses and the effective implementation of cost control measures [1]

Core Viewpoint - Zhijiang Biotechnology (688317.SH) is expected to report a net loss attributable to shareholders of the parent company for the year 2025, with estimates ranging from -32 million to -47 million yuan, indicating a significant decline in profitability compared to the previous year [1] Financial Performance - The projected net loss represents an increase in loss of 80.4621 million to 95.4621 million yuan compared to the same period last year, reflecting a year-on-year reduction in loss margin of 63.13% to 74.89% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -39 million and -58 million yuan, with a reduction in loss of 70.2713 million to 89.2713 million yuan compared to the previous year, indicating a year-on-year reduction in loss margin of 54.78% to 69.60% [1] Reasons for Performance - The primary reasons for the company's expected losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate on self-produced reagent products to 13%, which has negatively impacted revenue [1] - Additionally, a decrease in financial income and foreign exchange gains has contributed to the overall performance decline [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1] - The narrowing of losses this year is attributed to a reduction in asset impairment losses and the effective implementation of cost control measures [1]

证券代码：688317 证券简称：之江生物 公告编号：2026-004 上海之江生物科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 （一）利润总额：-15,057.09 万元。归属于母公司所有者的净利润： -12,746.21 万元。归属于母公司所有者的扣除非经常性损益的净利润： -12,827.13 万元。 （二）每股收益：-0.67 元。 三、本期业绩变化的主要原因 （一）本报告期公司业绩亏损的主要原因：公司主要产品销量下降、集采政 策陆续执行导致价格下降和自产试剂产品增值税税率调整为 13%导致收入下降； 财务收益的下降和汇兑损益减少等原因导致业绩亏损。同时公司在积极应对市场 竞争情况，加强产品研发，优化降本增效举措，挖掘潜力，不断提高产品的市场 竞争力，提升公司经营能力。 （二）公司本年度亏损收窄的原因：主要是资产减值损失的减少和成本费用 控制措施的有效实施。 四、风险提示 2025 年 1 月 1 日至 2025 年 12 月 ...

智通财经APP讯，之江生物(688317.SH)发布2025年年度业绩预告，预计实现归属于母公司所有者的净 利润-3,200万元到-4,700万元。与上年同期相比，净利润将减少亏损8,046.21万元到9,546.21万元，同比 减亏幅度63.13%到74.89%。 报告期公司业绩亏损的主要原因：公司主要产品销量下降、集采政策陆续执行导致价格下降和自产试剂 产品增值税税率调整为13%导致收入下降;财务收益的下降和汇兑损益减少等原因导致业绩亏损。同时 公司在积极应对市场竞争情况，加强产品研发，优化降本增效举措，挖掘潜力，不断提高产品的市场竞 争力，提升公司经营能力。 ...

之江生物公告，预计2025年年度实现归属于母公司所有者的净利润将出现亏损，预计实现归属于母公司 所有者的净利润-3200万元到-4700万元。与上年同期相比，净利润将减少亏损8046.21万元到9546.21万 元，同比减亏幅度63.13%到74.89%。 ...

证券日报网讯1月21日，之江生物在互动平台回答投资者提问时表示，公司欧盟销售收入占比相对较 低，目前未在欧盟国家设立子公司，主要通过代理的形式销售。 ...

来源：市场资讯 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向之江生物提问："董秘您好，请问贵公司有布局创新药和AI医疗方向吗？" 针对上述提问，之江生物回应称："尊敬的投资者，您好。公司围绕'预防、诊断、治疗'一体化战略， 持续以创新驱动发展。公司在创新药与AI医疗领域均有布局，依托智能制造、数字孪生等技术持续提 升感染性疾病、优生优育、肿瘤及遗传病诊断等多个领域的解决方案。感谢您的关注！" ...

每经AI快讯，有投资者在投资者互动平台提问：请问公司近年是否存在向欧盟成员国出口或销售的相 关业务？如有，欧盟地区业务收入在公司整体营业收入中的占比大致为多少？ 之江生物（688317.SH）1月21日在投资者互动平台表示，公司欧盟销售收入占比相对较低，目前未在 欧盟国家设立子公司，主要通过代理的形式销售。感谢您的关注！ （文章来源：每日经济新闻） ...

（文章来源：每日经济新闻） 之江生物（688317.SH）1月21日在投资者互动平台表示，公司围绕"预防、诊断、治疗"一体化战略，持 续以创新驱动发展。公司在创新药与AI医疗领域均有布局，依托智能制造、数字孪生等技术持续提升 感染性疾病、优生优育、肿瘤及遗传病诊断等多个领域的解决方案。 每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问贵公司有布局创新药和AI医疗方向 吗？ ...

格隆汇1月21日丨之江生物(688317.SH)在投资者互动平台表示，公司欧盟销售收入占比相对较低，目前 未在欧盟国家设立子公司，主要通过代理的形式销售。 ...